

PRIOR AUTHORIZATION REQUEST Platelet Inhibitors

PATIENT:	Name	Prescriber:	Name
	Address:		Address
	City, State, Zip	<u>.</u>	City, State, Zip
	D.O.B		Phone
	Member ID:	_	Fax
		NPI	
	Medication Requested:	Qty Re	equested:

Your patient's prescription benefit requires that we review certain requests for coverage with the prescriber. You have prescribed a medication for your patient that requires Prior Authorization before benefit coverage or coverage of additional quantities can be provided. Please complete the following questions then fax this form to the toll free number listed below. Upon receipt of the completed form, prescription benefit coverage will be determined based on the plan's rules.

SECTION A Please answer the following questions

- 1. Is this a request for INITIAL or CONTINUATION of therapy with the requested medication?
 - θ INITIAL \rightarrow please answer questions 2 18
 - θ CONTINUATION → please answer question 19 20
- 2. What is the indication or diagnosis?
 - Acute coronary syndrome (ACS) (for example, unstable angina, SEMI, NSTEMI)
 - θ All other indications

			If the prescribed drug is Effient, please answer questions 3 - 8
3.	θYes	θ Νο	Has the patient tried and failed OR has a contraindication/intolerance to clopidogrel?
4.	θ Yes	θ Νο	Is the patient a poor CYP2C19 metabolizer?
5.	θ Yes	θ Νο	Does the patient have active pathological bleeding, history of intracranial hemorrhage, or planned CABG?
6.	θ Yes	θ Νο	Is the patient considered a high thromboembolic risk?
7.	θ Yes	θ Νο	Is the patient taking concomitant 75-325mg/day aspirin?
8.	θ Yes	θ Νο	Does the patient have a history of TIA or stroke?
			If the prescribed drug is Brilinta, please answer questions 9 - 13
9.	θYes	θ Νο	Has the patient tried and failed OR has a contraindication or intolerance to clopidogrel?
10.	θ Yes	θ Νο	Does the patient have an active pathological bleeding, history of intracranial hemorrhage, or planned coronary artery bypass graft (CABG)?
11.	θ Yes	θ Νο	Is the patient taking concomitant 75-100mg/day aspirin?
12.	θ Yes	θ Νο	Does the patient have a severe hepatic impairment?
13.	θYes	θ Νο	Does the patient have a concomitant use with medications known to interact with Brilinta (for example, potent CYP3A4 inhibitors/inducers and simvastation or lovastatin in doses GREATER THAN 40mg/day)?

Continued on Page 2 Page 1 of 2

If you have any questions, call: 800-753-2851



PRIOR AUTHORIZATION REQUEST Platelet Inhibitors

Continued from Page 1

			f the prescribed drug is Zontivity, please answer questions 14 - 18
14.	θYes	θ Νο	Is the requested medication being prescribed for a patient with peripheral artery disease (PAD) or history myocardial infarction (MI)?
15.	θ Yes	θ Νο	Is the requested medication being used with aspirin and/or clopidogrel according to the standard of care for the patient's diagnosis?
16.	θ Yes	θ Νο	Does the patient have an active pathological bleeding?
17.	θ Yes	θ Νο	Does the patient have a history of stroke, transient ischemic attack (TIA), or intracranial hemorrhage (ICH)?
18.	θ Yes	θ Νο	Does the patient have a concomitant use with potent CYP3A4 inhibitors or inducers?
		If t	the prescribed drug is Effient or Brilinta , please answer question 19
			If the prescribed drug is Zontivity , please answer question 20
19.	θYes	θ Νο	Does the patient have a history of stent restenosis?
20.	θ Yes	θ Νο	Is this a request for Zontivity for a patient with peripheral artery disease (PAD) or a history of MI (myocardial infarction)?

Please document the diagnoses, symptoms, and/or any other information important to this review:

SECTION B

Physician Signature

PHYSICIAN SIGNATURE

DATE

FAX COMPLETED FORM TO: 877-251-5896

Page 2 of 2

Disclaimer: An authorization is not a guarantee of payment. Member must be eligible at the time services are rendered. Services must be a covered Health Plan Benefit and medically necessary with prior authorization as per Plan policy and procedures.

Confidentiality: The information contained in this transmission is confidential and may be protected under the Health Insurance Portability and Accountability Act of 1996. If you are not the intended recipient any use, distribution, or copying is strictly prohibited. If you have received this facsimile in error, please notify us immediately and destroy this document.

If you have any questions, call: 800-753-2851